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Abstract
Background: Gut microbiota play a key role in maintaining homeostasis in the human gut. Alterations in the gut
microbial ecosystem predispose to Clostridium difficile infection (CDI) and gut inflammatory disorders such as
inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) from a healthy donor can restore gut
microbial diversity and pathogen colonization resistance; consequently, it is now being investigated for its ability
to improve inflammatory gut conditions such as IBD. In this study, we investigated changes in gut microbiota
following FMT in 38 patients with CDI with or without underlying IBD.
Results: There was a significant change in gut microbial composition towards the donor microbiota and an overall
increase in microbial diversity consistent with previous studies after FMT. FMT was successful in treating CDI using a
diverse set of donors, and varying degrees of donor stool engraftment suggesting that donor type and degree of
engraftment are not drivers of a successful FMT treatment of CDI. However, patients with underlying IBD experienced
an increased number of CDI relapses (during a 24-month follow-up) and a decreased growth of new taxa, as compared
to the subjects without IBD. Moreover, the need for IBD therapy did not change following FMT. These results
underscore the importance of the existing gut microbial landscape as a decisive factor to successfully treat CDI
and potentially for improvement of the underlying pathophysiology in IBD.
Conclusions: FMT leads to a significant change in microbial diversity in patients with recurrent CDI and complete
resolution of symptoms. Stool donor type (related or unrelated) and degree of engraftment are not the key for
successful treatment of CDI by FMT. However, CDI patients with IBD have higher proportion of the original community
after FMT and lack of improvement of their IBD symptoms and increased episodes of CDI on long-term follow-up.
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Background
Gut microbiota play a key role in maintaining homeostatic
host functions, and deleterious shifts in the gut microbial
ecosystem, often referred to as dysbiosis, are associated
with Clostridium difficile infection (CDI), inflammatory
bowel disease (IBD), and other systemic inflammatory
conditions [1]. A diverse gut microbial community confers
colonization resistance against pathogens such as C. diffi-
cile, and disruption of a diverse community structure from
antibiotics, comorbidities, altered gastrointestinal transit,
or other risk factors can lead to pathogen colonization and
infection [2].
With increasing incidence of community and hospital
acquired CDI, high rates of recurrent CDI (estimated
20–30% after a first and 50–60% after a third infection),
high mortality (~29,000 deaths annually) in the USA,
and an urgent need for newer non-antibiotic therapies
has led to the emergence of microbiome-based therapies
[3]. Fecal microbiota transplantation (FMT) in CDI
patients restores phylogenetic diversity to levels more
typical of a healthy person, with response rates >85%
by enema, oral capsule, or endoscopic delivery modes
[4–6]. A recent study suggests significantly lower response
of CDI to FMT in patients with underlying inflammatory
bowel disease (IBD) [7]. We have also previously described
a higher rate of recurrence of CDI following FMT in pa-
tients with CDI and underlying IBD [8]. It remains unclear
if changes in gut microbial ecology play a role in long-
term success of FMT in these patients.
FMT has not shown consistent success in treating
other diseases associated with microbial dysbiosis such
as IBD. Three clinical trials to treat ulcerative colitis
(UC) with FMT have shown conflicting results, and one
highlighted the potential role of specific gut microbial
members in donor stool in determining success after
FMT in UC [9–11]. The underlying host or donor factors
that may be important for success of FMT in treatment of
IBD remain unclear.
In this study, we assessed the effect of donor type
(standard donor versus related donor) and changes in
gut microbial ecology on response to FMT in recurrent
CDI with and without underlying IBD as well as clinical
response to FMT.
Methods
Patient selection
Patients undergoing FMT for recurrent CDI were pro-
spectively recruited in this study. Informed consent was
obtained to collect clinical data and stool samples. Data
collected included demographics, clinical history, CDI
treatment history, comorbid conditions, and response to
FMT. A donor fecal sample was collected prior to FMT.
Stool samples from the recipients were collected before
FMT, and at day 7 and day 28, and were stored at −80 °C.
The donors were either related (genetically related family
members) or unrelated (screened hospital employee vol-
unteer donors or unrelated family members), and a fresh
sample was obtained on the day of FMT. All donors
underwent extensive screening in accordance with stand-
ard practice and guidelines from the Food and Drug Ad-
ministration [12]. Donor selection criteria and experience
from our group have been previously published [13]. The
donor stool sample is weighed and divided into 50 g ali-
quots. Each aliquot of 50 g is diluted in normal saline in a
1:5 ratio (50 g of stool diluted with 250 ml of normal sa-
line) and is placed in the blender bag (a two-bag system
with a semipermeable membrane in the inner bag and the
outside bag is plastic). The stool is placed in the inner bag
and normal saline is added. The bag is placed in a sealed
compartment in the stomacher 400 (Seward) and blended
for 60 s at 230 rotations per minute. The filtrate is then
placed into 50 ml conical tubes using 50 ml pipettes and
placed on an ice pack prior to the procedure. Recurrent
CDI was defined as another episode of CDI within 56 days
after symptom resolution with recurrence of symptoms
and a positive stool polymerase chain reaction test. For
this study, future C. difficile episodes after FMT up to
2 years were captured. These were categorized as up to
56 days, 56 days to 1 year, and beyond 1 year.
Sequencing and analytic methods
After fecal DNA isolation (MoBio, Carlsbad, CA fecal
DNA kit), amplicons spanning the variable region 4 of
bacterial 16S rRNA were generated and sequenced using
Illumina MiSeq platform at the Mayo Clinic Medical
Genome Facility, Rochester, MN. The 16S rRNA sequen-
cing data from the Illumina runs were quality controlled,
trimmed, demultiplexed, and assigned to operational
taxonomic units (OTUs) following the closed reference
at 97% similarity (using SortMeRNA as a clustering algo-
rithm [14] protocol against the Greengenes [15] database
13_8 release, as implemented in Quantitative Insights
Into Microbial Ecology (QIIME) 1.9.0 software [16], de-
fault parameters were used for all these steps unless other-
wise noted. After quality control, 10,583,052 sequences
were obtained, for a mean of 76,688 sequences per sample
(min: 33,559, max: 154,200).
Alpha diversity values were calculated using Faith’s
phylogenetic diversity [17]. To assess differential abundance
between the groups, we used ANCOM [18], as imple-
mented in scikit-bio 0.5.1 (http://scikit-bio.org/docs/0.5.1/).
This is tested by looking at the individual OTUs across the
patient types (with and without underlying IBD); OTUs of
the same genus are grouped for displaying purposes. We
note that ANCOM makes the statistical assumption that
fewer than 25% of taxa change, not met in all these com-
parisons (before FMT and post FMT communities are ex-
pected to be very different [19]). The donor plane is created
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using all the donor samples and serves as a proxy for where
their microbiomes are in the ordination space, and how as
time goes by this proximity changes. This procedure was
originally presented by Halfvarson et al. [20].
Beta diversity matrices were created using unweighted
UniFrac [21] and plotted using Emperor [22] (all other
plotting was done using the Seaborn visualization package).
Processed tables and sample information can be found
in Qiita (https://qiita.ucsd.edu) under study id 10057; al-
ternatively, the data can be found under accession number
ERP021216 at the European Bioinformatics Institute.
SourceTracker analysis
To assess the proportion of pre-transplant communities
that were retained in the patients’ microbiota, we used
SourceTracker [23]. The pre-transplant samples and the
donor samples were described as sources; all the other
samples were used as sinks. For all samples at days 7 and
28, SourceTracker estimated the proportion of commu-
nities that were attributed 1 of 3 environments, (1) the
donor, (2) the patient pre-transplant, and (3) unknown
community. Using these proportions, we grouped the
samples according to their IBD status and compared
their distributions using the Mann-Whitney test (as im-
plemented in SciPy 0.15.1 [24]).
Clinical statistics
Statistical analyses for clinical data were performed with
JMP version 11.0 (SAS institute, NC). Data analysis in-
cluded descriptive statistics, t tests for normally distributed
variables, non-parametric tests for skewed variables, chi-
square tests, and ANOVA tests as applicable. A p value less
than 0.05 was considered statistically significant.
Results
FMT leads to resolution of CDI
In order to assess gut microbiota changes following
FMT, 38 patients with recurrent CDI were enrolled in
the study and a fecal sample was obtained prior to trans-
plant, as well as 7 and 28 days post-transplant. Sample
handling, donor and recipient sample collection, sample
processing, and data analyses are detailed in supplemen-
tary methods. FMT was accomplished by colonoscopy
using fresh donor stools from related (n = 12) or unre-
lated (n = 26) donors. None of the IBD patients received
stool from a related donor. The demographic, disease,
and treatment characteristics are outlined in Table 1.
Detailed characteristics of IBD patients are shown in
Additional file 1: Table S1. Twelve patients (31.6%) had
IBD (6 with UC and 6 with Crohn’s disease), with me-
dian age 27.6 years (range 23.3–74.9), and median IBD
duration 5 years (range 2–33). 58.3% of patients were on
5-ASA (amino salicylic acid) agents, 50% on biologics,
33.3% on immunomodulators, and 58.3% on steroids.
Among patients with IBD, at the time of colonoscopy, 2
had normal colonoscopy, 1 had pseudopolyps, 5 had se-
vere pancolitis, 1 had moderate colitis, 1 had mild colitis,
1 had mild procto-sigmoiditis, and 1 had moderate ileo-
colitis (Additional file 1: Table S1).
All patients responded to FMT with regards to clinical
or microbiologic remission of CDI (negative C. difficile
testing in the presence of ongoing diarrhea), 92.1%
(n = 35) of patient symptoms returned to baseline bowel
pattern (as before CDI) and resolution of CDI, 5.3% (n = 2,
both with IBD) had worsening diarrhea (C. difficile nega-
tive), and 2.6% (n = 1) had new onset constipation after
FMT. Upon long-term follow-up of 24 months; 13.2%
(n = 5/38; of these, n = 1 within 56 days, n = 1 from
Table 1 Clinical characteristics
Overall (n = 38) IBD (n = 12) No IBD (n = 26)
Age, median (range) 53.1 (21.9–82.7) 27.6 (23.3–74.9) 58.3 (21.9–82.7)
Sex distribution (% female) 81.6 66.7 88.5
BMI, kg/m2 median (range) 24.8 (14.9–39.9) 25.6 (18.5–30.3) 23.8 (14.9–39.9)
Number prior CDI episodes, median (range) 5 (3–13) 4.5 (3–7) 5 (3–13)
Number prior metronidazole courses, median (range) 1 (0–8) 1 (0–2) 1 (0–8)
Patients treated with at least one prior course of metronidazole, n (%) 33 (86.8%) 9 (75%) 24 (92.3%)
Number prior vancomycin 10–14 day courses, median (range) 2 (0–4) 2 (0–4) 2 (0–3)
Patients treated with at least one prior course of vancomycin, n (%) 36 (94.7%) 11 (91.7%) 25 (96.2%)
Number prior vancomycin tapers, median (range) 1 (0–5) 1 (0–1) 1 (0–5)
Patients treated with at least one prior course of vancomycin taper, n (%) 26 (68.4%) 7 (58.3%) 19 (73.1%)
Number prior fidaxomicin courses, median (range) 0 (0–4) 0 (0–2) 0 (0–4)
Patients treated with at least one prior course of fidaxomicin, n (%) 16 (61.5%) 5 (41.7%) 16 (61.5%)
Related donors, n (%) 12 (31.6%) 0 (0%) 12 (46.2%)
Recurrent CDI within 24 months of FMT, n (%) 5 (13.2%) 3 (25%) 2 (7.7%)
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56 days to 1 year, and n = 3 beyond 1 year, Additional
file 1: Table S2) had another episode of CDI and 10.5%
(n = 4/38) required a second FMT due to multiply re-
current CDI. One patient with rCDI was treated with
vancomycin. The risk of another episode of CDI after
FMT in IBD patients was 25% (n = 3/12) compared to
7.7% (n = 2/26) in non-IBD patients (p = 0.16, chi-square
test). Seven of the 12 patients with IBD were on systemic
immunosuppression. None of the patients with IBD had
improvement in their IBD course after FMT, and none
were able to withhold, de-escalate, or stop IBD treatment.
This is in agreement with other studies showing a lack of
improvement in IBD following a single FMT.
FMT decreases microbial dysbiosis
FMT led to a significant increase in alpha diversity based
on Faith’s phylogenetic diversity, Shannon’s diversity
index, and observed species, both at day 7 and day 28
(Mann-Whitney p < 0.05; Additional file 2: Figure S1,
comparing pre- and post-FMT in patients with CDI with
or without underlying IBD). Also, patient’s stool closely
resembled donor stool, as evidenced by a rapid and
sustained change in unweighted and weighted UniFrac-
based beta diversity following FMT at day 7 and 28 post-
transplant (Fig. 1a; PERMANOVA p < 0.05) [21].
To characterize the changes in community compos-
ition, we use the microbial dysbiosis index (MD index)
as a reference to describe the dominance of individual
taxa (Additional file 1: Table S3). The MD index is com-
posed of 18 taxonomic groups, as defined by Gevers
et al., with a higher value correlated with greater disease
severity in IBD and lower values associated with health-
ier states [25]. As CDI is also associated with dysbiosis
and inflammation, we wanted to determine the effect of
FMT on dysbiosis. The MD index values were signifi-
cantly higher in patients with CDI compared to donors
(Mann-Whittney’s U, p < 0.05, Fig. 1b). However, on days
7 and 28 after the transplantation, the MD index values
were similar to donors (Mann-Whitney’s U p > 0.05,
Fig. 1b) and this change was independent of whether re-
cipients had IBD or not.
In order to determine if the changes seen in our subjects
following FMT were similar to other published studies, we
compared our samples with recently published data from
Weingarden et al. 2015 (Additional file 3: Figure S2A)
wherein four patients with recurrent CDI (but not IBD)
received FMT from a single donor [19]. Similar to our
findings, there was a rapid and sustained change in beta
diversity (Additional file 3: Figure S2A) following FMT
and the regression to the donor plane (change in microbial
Fig. 1 a Principal Coordinates Analysis of the unweighted UniFrac distances, showing a significant change in the phylogenetic diversity between
patients with CDI, 7 and 28 days after fecal microbiota transplant (PERMANOVA p < 0.05). b Change in dysbiosis index following fecal microbiota
transplant in patients with CDI with or without IBD, demonstrating that the microbial dysbiosis index values were significantly higher in patients
with CDI compared to donors (Mann-Whittney’s U, p < 0.05). c Spearman correlation to donor stool 7 and 28 days following fecal microbiota
transplantation demonstrating that the fecal microbial communities from patients with CDI were distinct from donor communities prior to
transplant (Spearman’s r < 0.2 for all subjects)
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composition to resemble healthy donors) following FMT
was remarkably similar in the two studies (Additional file
3: Figure S2B). In this context, we refer to the donor plane
as a proxy to the region in the Principal Coordinates
Analysis (PCoA; a dimensionality reduction method to
visualize beta-diversity distance matrices) space where
the donors are located; we do this by fitting a three-
dimensional plane (using the least squares method) to
the samples from the donors. As the communities change
post-FMT, the distance to this plane is reduced.
Clinical response of CDI to FMT is independent of
engraftment or donor type but underlying IBD influences
changes in gut microbial ecology after FMT
In order to determine if the response of CDI to FMT was
dependent on donor stool engraftment, we determined
Spearman’s correlation coefficient between fecal microbial
communities prior to 7 and 28 days post-transplant. The
fecal microbial communities from patients with CDI were
distinct from donor communities prior to transplant
(Spearman’s r < 0.2 for all subjects, Fig. 1c). Following
transplant, communities showed an increase in correlation
to donor stool at day 7 (Spearman’s r > 0.4 for 85% of the
subjects, Fig. 1c) and a spread for all subjects at day 28
ranging from below 0.2 up to 0.6 (Fig. 1c). Using Source-
Tracker [23], we found that after FMT, subjects with IBD
retained a higher proportion of their original communities
(Mann-Whitney p < 0.05 at day 7, and p = 0.06 at day 28;
Fig. 2a, b) and a significantly lower proportion of new
communities (Mann-Whitney p < 0.05 at days 7 and 28),
as compared to the patients without IBD. The expansion
of new taxa following FMT as seen in patients without
IBD may represent a beneficial ecological change following
FMT; however, future studies will be needed to address
the biological effect of newly acquired community mem-
bers following FMT. Consequently, in patients with IBD,
we observed a smaller group of taxa that change signifi-
cantly 7 days after FMT. In both groups, Bacteroides
and Faecalibacterium showed a significant increase in
relative abundance, with Blautia, only being increased
for patients without IBD. Additionally, these patients
showed a decrease in relative abundance of Lactobacillus,
Veillonella, Enterobacter, Klebsiella, Erwina, Proteus, Sal-
monella, and Trabulsiella (Fig. 2c, d, ANCOM p < 0.05,
corrected for multiple comparisons using Bonferroni-
Holm’s method [18]).
All patients had either clinical or microbiological re-
mission (negative C. difficile testing in the presence of
ongoing diarrhea) confirming that initial response of
CDI to FMT is not dependent on the degree of donor
stool engraftment. In this small cohort of patients, those
with underlying IBD had higher number of late relapses
of CDI. We found no significant differences in gut
microbiota composition following FMT from standard
donors or related donors (Mann-Whitney p > 0.05 at days
7 and 28), suggesting that engraftment of donor stool was
independent of donor type. Furthermore, as all patients
had ongoing clinical remission with microbiological re-
sponse (if measured), donor type does not appear to affect
CDI-related clinical response.
Change in bacterial diversity after FMT is dependent on
underlying IBD
IBD disease course, as measured by the need for specific
IBD therapies, did not change after FMT, and patients
with CDI and underlying IBD retained a higher proportion
of the pre-transplant communities and lower proportion
of new communities following FMT. Thus, underlying
IBD appears to affect the change in gut microbial ecology
resulting in a less significant increase in overall diversity.
In subjects without IBD, Faith’s phylogenetic diversity
(which measures the total branch length of a phylogenetic
tree that a given sample covers [26]) reached a level com-
parable to healthy donors (Mann-Whitney’s U p < 0.001,
Fig. 2e). The differences in phylogenetic diversity following
FMT between subjects with and without IBD became evi-
dent on day 7 and persisted on day 28 (Mann-Whitney,
day 1 p = 0.163, day 7 p = 0.0058, and day 27 p = 0.008,
Fig. 2e). A linear regression of phylogenetic diversity ver-
sus MD index (Additional file 4: Figure S3) shows a sig-
nificantly lower negative correlation between the increase
in phylogenetic diversity and the increase of the MD index
in patients with IBD (Pearson’s correlation coefficient, IBD
R = −0.68, no IBD R = −0.83; p < 0.0001; Additional file 4:
Figure S3) suggesting a lack of recovery of phylogenetic di-
versity in patients with IBD as the MD index improves.
Discussion
In this study, we found that gut microbiota diversity
changes rapidly following FMT for treatment of CDI and
resembles donor microbiota diversity, similar to previous
studies. A successful response of CDI to FMT was seen
with a diverse group of donors and at levels of engraft-
ment (as measured by correlation to donor stool) vary-
ing from 50 to 94% (at day 7) and 34–93% (at day 28)
based on the proportion of communities attributed to
the donor following FMT per SourceTracker, suggesting
these are not critical factors in determining response.
Similarly, a recent study that evaluated pre- and post-
FMT (for recurrent CDI) gut microbiome samples from
a subset of patients enrolled in a randomized controlled
trial [27], compared donor FMT to autologous FMT sug-
gested that complete engraftment of donor bacteria may
be not necessary, if functionally, critical taxa are present
in subjects following initial antibiotic therapy for CDI
[28]. This study excluded patients with IBD but was able
to compare autologous to donor FMT unlike our study.
There was a higher number of recurrent CDI following
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FMT in patients with CDI and IBD, but this was not sta-
tistically significant, likely given the small sample size.
However, we have previously reported similar findings in
a larger cohort of patients with CDI and IBD [8], where
gut microbiota changes were not monitored. Interest-
ingly, in this cohort, all patients had an initial clinical or
microbiological remission (negative C. difficile testing in
the presence of ongoing diarrhea) of CDI following FMT,
and we did not see a difference in initial response reported
in a recent study [7], which is also likely due to the smaller
sample size of our study and differences in underlying dis-
ease characteristics.
We also did not see changes in need for IBD therapy
in the subset of patients with IBD underlying CDI.
While dynamic variations can be seen in patients follow-
ing FMT [19], patients with underlying IBD in our study
show a higher proportion of the original pre-transplant
microbial community and lower recovery of phylogen-
etic diversity following FMT compared to those without
IBD. This lack of beneficial change in microbial ecology
may be relevant for long-term response of CDI in pa-
tients with IBD and the lack of clinical response of IBD
to FMT seen in our and previous studies [7]. Future
studies designed to study the effect of compositional and
Fig. 2 a, b Subjects with IBD retain a higher proportion of their original communities (*Mann-Whitney p < 0.05 at day 7 and p = 0.06 at day 28,
and a significantly lower proportion of new communities (*Mann-Whitney p < 0.05 at days 7 and 28), as compared to the patients without IBD
using SourceTracker. c Bacterial taxa that change significantly in patients with IBD after FMT (ANCOM p < 0.05, corrected for multiple comparisons
using Bonferroni-Holm’s method). d Bacterial taxa that change significantly in patients without IBD after FMT (ANCOM p < 0.05, corrected for
multiple comparisons using Bonferroni-Holm’s method). e Change in phylogenetic diversity-based alpha diversity 7 and 28 days following
fecal microbiota transplant in patients with CDI with and without IBD (Mann-Whitney’s U p < 0.001)
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functional changes in gut microbiota on clinical outcomes
following FMT in patients with IBD will be needed to de-
finitively address the potential importance of changes in
microbial ecology, donor selection [9], underlying disease
characteristics, and multiple-dose FMTs, in correcting the
underlying pathophysiology of IBD.
Conclusions
There is a significant increase in microbial diversity in
patients with recurrent CDI after FMT. Both the degree
of microbial engraftment or donor type (related or unre-
lated) are not the key for successful treatment of recurrent
CDI by FMT. Compared to CDI patients without IBD, CDI
patients with IBD have higher proportion of the original
microbial communities after FMT and increased episodes
of future CDI on long-term follow-up.
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